Most people learn what cancer treatment looks like from someone they love going through it: the exhaustion after chemotherapy, the burns from radiation, the months of recovery. For decades, those were the only options. Today, a different category of treatment is changing what's possible: immunotherapy.
Immunotherapy doesn't attack cancer the way chemo does. It works differently, and that difference matters enormously for patients who want effective treatment without destroying their quality of life in the process. This article explains what immunotherapy is, how it works at a biological level, which types exist, who it can help, and what patients should realistically expect from it.
What Is Immunotherapy?
Immunotherapy is a category of cancer treatment that uses the body's own immune system, or laboratory-made versions of immune system components, to identify, target, and eliminate cancer cells.
The core insight behind it is straightforward: your immune system already knows how to fight threats. It destroys viruses, clears out damaged cells, and patrols for abnormalities every single day. The problem with cancer is that tumor cells have learned to disguise themselves. They produce proteins that send a "do not attack" signal to immune cells, or they simply fly below the radar of immune detection. Immunotherapy removes those disguises and restores the immune system's ability to do its job.
This is fundamentally different from chemotherapy, which works by killing rapidly dividing cells, a category that includes both cancer cells and many healthy ones (which is why hair loss, nausea, and immune suppression are such common side effects). Immunotherapy is far more targeted. It goes after the cancer without the indiscriminate collateral damage.
How Does the Immune System Normally Fight Cancer?
Understanding immunotherapy starts with understanding normal immune function.
Your immune system has two main branches: the innate immune system (a fast, general-purpose defense) and the adaptive immune system (a slower but highly specific response). The adaptive arm is the one that matters most for cancer.
Within the adaptive immune system, T cells are the primary fighters. They patrol the body looking for cells displaying abnormal proteins called antigens. When a T cell detects a cancer antigen, it should lock on and destroy that cell. But cancer cells are crafty; they evolve mechanisms to block T cell activation, suppress immune signals, and create a microenvironment around the tumor that actively suppresses immune activity.
Immunotherapy works by intervening in this process at multiple points.
The Main Types of Immunotherapy in Cancer Treatment
There is no single "immunotherapy." It's a broad term that includes several different approaches, each working through a different mechanism.
1. Immune Checkpoint Inhibitors
Checkpoints are molecular switches that regulate immune activity. Normally, they exist to prevent the immune system from going into overdrive and attacking healthy tissue. Cancer cells exploit these checkpoints by essentially "hitting the brakes" on T cells before they can destroy the tumor.
Checkpoint inhibitors are drugs that block those brake signals, specifically proteins like PD-1, PD-L1, and CTLA-4. When the brakes are released, T cells can attack the tumor again. Drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) work this way and have produced durable responses in melanoma, lung cancer, and several other cancers. According to the National Cancer Institute, checkpoint inhibitors are now approved for more than a dozen cancer types.
2. Cellular Therapy (Including CAR T-Cell Therapy)
Cellular therapy involves collecting immune cells from a patient, engineering or activating them in a lab, and infusing them back to fight cancer.
The most advanced version is CAR T-cell therapy (Chimeric Antigen Receptor T-cell therapy). Here, a patient's T cells are genetically reprogrammed to express a receptor that locks specifically onto cancer cell antigens. These engineered cells are then multiplied in the lab and reinfused into the body, where they hunt and destroy cancer cells with high precision.
At Immunotherapy Institute, CAR T-cell therapy is part of an integrated treatment strategy. You can learn more about our approach to CAR T-cell therapy in Mexico.
3. Autologous Immunotherapy (Cancer Vaccines)
Autologous immunotherapy uses the patient's own cells or tumor material to create a highly personalized immune response. Unlike conventional vaccines that prevent infection, cancer vaccines are therapeutic; they train the immune system to recognize and attack a tumor that's already present.
At Immunotherapy Institute, autologous immunotherapy is a cornerstone of our treatment model. We extract information from the patient's own cancer and use it to develop a personalized immune strategy, rather than applying a one-size-fits-all protocol.
4. Monoclonal Antibodies
Monoclonal antibodies are lab-engineered proteins designed to bind to specific targets on cancer cells. Some work by tagging cancer cells for destruction by the immune system. Others deliver toxic payloads directly to tumor cells (called antibody-drug conjugates). Others block the signals tumors use to grow new blood vessels (anti-angiogenics).
5. Cytokines
Cytokines are signaling proteins that regulate immune activity. In therapeutic settings, high doses of certain cytokines, like interleukin-2 (IL-2) or interferon-alpha, can boost immune activity against cancer. They are sometimes used in combination with other immunotherapy approaches.
Immunotherapy vs. Chemotherapy: The Key Difference
One of the most common questions patients ask is how immunotherapy compares to chemotherapy.
Chemotherapy works by targeting all rapidly dividing cells. It's effective at shrinking tumors quickly, but the mechanism doesn't distinguish between cancer cells and healthy cells like hair follicles, gut lining, or bone marrow. This explains why systemic side effects are so severe.
Immunotherapy, by contrast, trains the body to distinguish cancer from healthy tissue. When it works well, the side effects are significantly different in character, often involving the immune system itself (fatigue, skin reactions, inflammatory symptoms) rather than the systemic toxicity of chemo.
Importantly, immunotherapy can produce responses that last far longer. A patient whose cancer responds to a checkpoint inhibitor may maintain that response for years, even after stopping treatment. Chemotherapy rarely achieves this kind of durable result.
That said, immunotherapy is not a magic solution. Not all patients respond, not all cancer types are equally immunogenic, and combining modalities is often necessary. At Immunotherapy Institute, our approach recognizes this: we combine targeted therapy, autologous immunotherapy, and functional medicine in a precision-based model designed to address cancer from multiple angles simultaneously.
You can learn more about our integrative treatment model on our Cancer Treatments page.
Who Is a Candidate for Immunotherapy?
Immunotherapy is not universally appropriate for every patient or cancer type, but its applications are expanding rapidly. Current evidence supports immunotherapy, often in combination with other treatments, for:
Lung cancer (non-small cell lung cancer, in particular)
Melanoma and skin cancers
Breast cancer (especially triple-negative subtypes)
Colorectal cancer (particularly MSI-H or dMMR subtypes)
Bladder cancer
Lymphomas (Hodgkin's and certain non-Hodgkin's)
Pancreatic, liver, and gastric cancers (in select cases)
Metastatic and stage 4 cancers where conventional options have limited effectiveness
Candidacy depends on several factors: the type and stage of cancer, the molecular profile of the tumor, the patient's immune status, and their overall health. At Immunotherapy Institute, every treatment plan begins with a thorough evaluation to determine which combination of therapies is most likely to produce results for that specific patient.
What Can Patients Realistically Expect?
Immunotherapy has produced some remarkable outcomes, including complete, long-lasting remissions in patients with cancers that had previously been considered untreatable. But setting realistic expectations matters.
Response rates vary significantly by cancer type and patient profile. In some cancers, such as advanced melanoma, roughly a third of patients respond to single-agent checkpoint inhibitors; response rates vary widely by cancer type and are lower for many tumors. In others, the rate is much lower without combination approaches.
Responses can be delayed. Unlike chemotherapy, which may produce visible tumor shrinkage quickly, immunotherapy sometimes causes what's called pseudoprogression, a temporary increase in tumor size as immune cells flood the area, before the cancer begins to regress. Patience and close monitoring are important.
Duration of response is often where immunotherapy stands apart. When patients do respond, many maintain that response for months or years.
Side effects are real but different: Immune-related adverse events (irAEs) can include fatigue, skin rash, colitis, endocrine disruption, and in rare cases more serious inflammatory reactions. Managing these requires close physician supervision.
At Immunotherapy Institute, we maintain a 3-year follow-up program for all our patients, not just to monitor for recurrence, but to actively support immune health and quality of life through recovery and beyond. Learn more about our follow-up care program.
Why Location Matters: Immunotherapy in Mexico
Access to advanced immunotherapy remains uneven. In the United States, the cost of some treatments, particularly CAR T-cell therapy, can exceed $400,000. Insurance coverage is inconsistent, and many patients face long waits or geographic barriers to academic medical centers.
Immunotherapy Institute is located in Tijuana, Mexico, just minutes from the US border, making advanced, personalized cancer treatment accessible to patients from the US and internationally, at a fraction of US costs and without compromising on scientific rigor or clinical standards.
Our multidisciplinary team brings together clinical oncology, immunotherapy, and functional medicine under one roof. Every protocol is designed around the individual patient, not a standardized treatment algorithm.
Frequently Asked Questions About Immunotherapy
Does immunotherapy work for all types of cancer?
Not universally. Some cancers, like melanoma, certain lung cancers, and some lymphomas, respond particularly well to immunotherapy. Others, like pancreatic cancer, have lower response rates. However, the field is advancing rapidly, and combinations with other treatments are expanding who can benefit. The best way to know if you're a candidate is through a personalized evaluation.
Is immunotherapy the same as a clinical trial?
No. Several immunotherapy treatments, including checkpoint inhibitors and CAR T-cell therapy, are already approved and used in standard clinical practice. Others are being refined through ongoing clinical trials. At Immunotherapy Institute, we offer established, evidence-backed protocols, not experimental treatments.
Can immunotherapy be combined with chemotherapy or radiation?
Yes, and this combination is increasingly common. Research shows that certain chemotherapy drugs and radiation can actually enhance the immune response, making immunotherapy more effective when the two are used together. At Immunotherapy Institute, we assess each patient to determine the optimal combination.
How long does immunotherapy treatment last?
Duration depends on the type of immunotherapy, the cancer being treated, and how the patient responds. Some patients receive treatment for a defined number of cycles; others continue as long as they're responding and tolerating the treatment.
What are the side effects of immunotherapy?
The most common are fatigue, skin reactions (rash, itching), and flu-like symptoms. Because immunotherapy activates the immune system, it can also cause inflammation in various organs: the gut, lungs, liver, or endocrine glands. These are called immune-related adverse events (irAEs) and require monitoring. Compared to chemotherapy, immunotherapy side effects are generally better tolerated, though they require attention and management.
Will immunotherapy work if chemotherapy didn't?
In many cases, yes. Immunotherapy and chemotherapy work through entirely different mechanisms. Patients who didn't respond to chemotherapy, or who relapsed after it, can still respond to immunotherapy, sometimes dramatically.
Take the Next Step
If you or someone you love is navigating a cancer diagnosis and wants to understand all available options, including advanced immunotherapy protocols, we're here to help. At Immunotherapy Institute, our team reviews each patient's case individually and provides honest, science-based guidance about what's possible.
Request a free consultation today and let us help you understand whether immunotherapy is right for you.
This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional regarding your specific situation.
Meta TitleWhat Is Immunotherapy and How Does It Work in Cancer Treatment?
Meta DescriptionLearn how immunotherapy works, the types available, who qualifies, and what results to expect. Discover how Immunotherapy Institute uses personalized immune-based cancer treatment.
**Preview (excerpt for blog listing / social)**Most people know what cancer treatment looks like from watching someone they love go through it. Today, immunotherapy is changing what's possible; not by attacking cancer with chemicals, but by training your own immune system to do the job. Here's how it works, who it helps, and what patients should realistically expect.